Genetic polymorphisms of vascular endothelial growth factor (VEGF) associated with gastric cancer recurrence after curative resection with adjuvant chemotherapy
Open Access
- 22 May 2019
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 483
Abstract
The relationship between polymorphisms in vascular endothelial growth factor (VEGF) and gastric cancer is still inconclusive. We investigated whether there is an association between VEGF genetic polymorphisms and risk of gastric cancer, and evaluated the recurrence of advanced gastric cancer after curative resection with adjuvant chemotherapy according to VEGF genetic polymorphisms. The association of functional single nucleotide polymorphisms (SNPs) of the VEGF gene (+936C > T, − 634G > C, − 2578C > A, + 1612G > A) were evaluated. Genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. A total of 151 patients with gastric cancer were enrolled, and the control group consisted of 413 individuals with esophago-gastroduodenoscopy who were randomly selected through health screening. All of the enrolled patients had curative resections with completion of adjuvant capecitabine and oxaliplatin combination chemotherapy and the initial metastatic cases were excluded. During the regular follow-up protocol, the episodes of the recurrence were documented and the specific genotype and allelic frequencies were evaluated. As for the cancer risk, there were no significant differences in specific genotypes and allelic frequencies. The mean follow-up period was 28.82 ± 30.92 (12 ~ 72) months and the recurrence rate was 28.3%. In the patients carrying the 936-C allele, the recurrence rate of gastric cancer was high (P = 0.02). Disease-free interval was significantly different between the patients carrying the 936-CC and 936-CT/TT genotype (P = 0.02). VEGF 936-C allele is associated with poor prognosis, but not risk of gastric cancer. In the patients carrying the 936-C allele, more potent adjuvant treatment would be considered.Keywords
This publication has 52 references indexed in Scilit:
- Vascular endothelial growth factor (VEGF) −2578C/A and −460C/T gene polymorphisms and lung cancer risk: a meta-analysis involving 11 case–control studiesTumor Biology, 2013
- The relationship of Vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancerBMC Cancer, 2013
- Influence of vascular endothelial growth factor single nucleotide polymorphisms on non-small cell lung cancer tumor angiogenesisOncology Reports, 2012
- Vascular endothelial growth factor +936C/T polymorphism and gastric cancer risk: A meta-analysisExperimental and Therapeutic Medicine, 2011
- Single nucleotide polymorphisms of the vascular endothelial growth factor gene associated with incidence of oral squamous cell carcinomaJournal of Oral Pathology & Medicine, 2010
- The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumorsMolecular Cancer Therapeutics, 2009
- The Clinicopathological Significance of Tissue Levels of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor in Gastric CancerGut and Liver, 2009
- Gender-specific Association between Polymorphism of Vascular Endothelial Growth Factor (VEGF 936C > T) Gene and Patients with Stomach CancerYonsei Medical Journal, 2008
- Association of VEGF genotype with mRNA level in colorectal adenocarcinomasBiochemical and Biophysical Research Communications, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003